Pdt Partners, LLC Pulmonx Corp Transaction History

Pdt Partners, LLC

$1.02 Billion
Q3 2024

A detailed history of Pdt Partners, LLC transactions in Pulmonx Corp stock. As of the latest transaction made, Pdt Partners, LLC holds 88,074 shares of LUNG stock, worth $558,389. This represents 0.07% of its overall portfolio holdings.

Number of Shares

88,074

Previous 70,290 25.3%

Holding current value

$558,389

Previous $445,000 64.04%

% of portfolio

0.07%

Previous 0.05%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$5.59 - $8.58 $99,412 - $152,586	17,784 Added 25.3%	88,074 $730,000
Q1 2024 May 15, 2024	BUY	$8.71 - $14.65 $337,016 - $566,852	38,693 Added 122.46%	70,290 $651,000
Q4 2023 Feb 14, 2024	BUY	$7.89 - $13.14 $284 - $473	36 Added 0.11%	31,597 $402,000
Q3 2023 Nov 14, 2023	SELL	$9.88 - $14.0 $79 - $112	-8 Reduced 0.03%	31,561 $326,000
Q2 2023 Aug 14, 2023	SELL	$10.78 - $13.65 $262,514 - $332,404	-24,352 Reduced 43.55%	31,569 $413,000
Q1 2023 May 15, 2023	SELL	$7.49 - $12.54 $133,629 - $223,726	-17,841 Reduced 24.19%	55,921 $625,000
Q4 2022 Feb 14, 2023	BUY	$4.92 - $17.35 $60,909 - $214,793	12,380 Added 20.17%	73,762 $621,000
Q3 2022 Nov 14, 2022	SELL	$15.35 - $23.99 $91,869 - $143,580	-5,985 Reduced 8.88%	61,382 $1.02 Million
Q2 2022 Aug 15, 2022	BUY	$14.0 - $27.95 $743,988 - $1.49 Million	53,142 Added 373.58%	67,367 $992,000
Q1 2022 May 16, 2022	BUY	$21.13 - $35.65 $300,574 - $507,121	14,225 New	14,225 $353,000
Q2 2021 Aug 16, 2021	SELL	$37.61 - $48.0 $180,076 - $229,824	-4,788 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$44.0 - $67.54 $210,672 - $323,381	4,788 New	4,788 $219,000

Others Institutions Holding LUNG

# of Institutions

123

Shares Held

31M

Call Options Held

300

Put Options Held

204K

View Full List

About Pulmonx Corp

Ticker LUNG
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 37,268,400
Market Cap $236M
Description
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...

More about LUNG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account